Forge Biologics snags $120m Series B
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, has secured $120 million in Series B financing.
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, has secured $120 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination